Jul 30, 2026 · 12 min · 9 segments
Jon Treffert was diagnosed with locally advanced muscle-invasive bladder cancer in September 2023. After 2 years of treatment, including surgical resection and 6 months with an antibody-drug conjugate…
John TreffertGuestSummer JohnsonHostHow did you first hear about ADCs? Is there anything you know now that you wish you had known then?
I was working for a radiation oncology software company based in Sweden when I saw blood in my urine.
And I was familiar with cancer from my pet work in terms of brain cancer, lung cancer, but bladder was not on my radar at all.
My GP was worried enough that we had a CT done that found some wall thickening that was suspicious for bladder cancer.
And he referred me to a urologist he knew where I had my first cystoscopy ever, where we saw a large tumor that was obstructing the right ureter and leading to a little bit of back pain due to hydronephrosis.
I got introduced, I was diagnosed under managed care, which was the first time I'd ever really needed insurance.
So I spent a lot of time at the local social security office trying to get that resolved.
And in that month, I learned of a presentation at the European Society of Medical Oncology meeting, the ESMO meeting in 2023.
Dr. Tom Powles received a standing ovation for the doubling of overall survival for locally advanced or metastatic MIBC with a combination of an antibody drug conjugate, infortimab, vedotin, and an immune checkpoint inhibitor, pembrolizumab.
How did you first hear about ADCs? Is there anything you know now that you wish you had known then?
I was working for a radiation oncology software company based in Sweden when I saw blood in my urine.
And I was familiar with cancer from my pet work in terms of brain cancer, lung cancer, but bladder was not on my radar at all.
My GP was worried enough that we had a CT done that found some wall thickening that was suspicious for bladder cancer.
And he referred me to a urologist he knew where I had my first cystoscopy ever, where we saw a large tumor that was obstructing the right ureter and leading to a little bit of back pain due to hydronephrosis.
I got introduced, I was diagnosed under managed care, which was the first time I'd ever really needed insurance.
So I spent a lot of time at the local social security office trying to get that resolved.
And in that month, I learned of a presentation at the European Society of Medical Oncology meeting, the ESMO meeting in 2023.
Dr. Tom Powles received a standing ovation for the doubling of overall survival for locally advanced or metastatic MIBC with a combination of an antibody drug conjugate, infortimab, vedotin, and an immune checkpoint inhibitor, pembrolizumab.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
